The treatment of numerous solid and hematologic malignancies (eg non‐small cell lung carcinoma, bladder carcinoma, melanoma, classical Hodgkin lymphoma) has been markedly improved due to therapy with immune check point inhibitors against programmed death 1 and its ligand PD‐L1 (immuno‐oncology [I‐O] treatment). Here, CD274 is linked to cancer.